Skip to main content
. 2017 Feb 4;8(9):14294–14305. doi: 10.18632/oncotarget.15104

Figure 2. Pravastatin via ROS activates AMPK in murine VSMCs.

Figure 2

A. Murine VSMCs were treated with pravastatin for 2 hours as indicated concentrations. Total cell lysates were subjected to perform western blot analysis of the levels of pAMPK-T172. The blot is a representative of three blots from three independent experiments. B.-E. Cultured VSMCs were pretreated with tempol (10 μM, 30 minutes) followed by co-incubation of pravastatin (50 μM) for 2 hours. Total cell lysates were subjected to perform western blot analysis of the levels of B. oxidative stress biomarkers of Nox4, p47 and 4-HNE and C. pAMPK-T172. ROS productions were determined by measuring DHE fluorescence in D. and performed quantitative analysis in E. N is 3 in each group. One-way ANOVA followed by Tukey post-hoc tests was used for multiple comparisons. In A, *P < 0.05 vs. point 0. In B., C. and E., *P < 0.05 vs. Control. NS indicates no significance.